Countering CCP Act

The Countering CCP Act requires the U.S. Food and Drug Administration to review medical devices made by Chinese manufacturers or those controlled by Chinese entities for potential cybersecurity vulnerabilities. Under this law, the agency must request detailed technical information from these companies within 180 days to assess whether patient data could be stored on servers in China or accessed by unauthorized parties. If a device is found to pose a cybersecurity risk or if a company fails to provide the requested information, the FDA can order an immediate recall and halt its distribution. Additionally, the bill mandates a comprehensive report on the cybersecurity preparedness of the U.S. medical device industry two years after the law takes effect.